Skip to main content
SpringerLink
Log in

Review of WHO 2016 Changes to Classification of Gliomas; Incorporation of Molecular Markers

  • Chapter
  • First Online:
Glioma Imaging

Abstract

In 2016, the World Health Organization (WHO) updated its brain tumor classification system to recognize the importance of key genetic alterations in glioma, incorporating these features into the definitions of a variety of brain tumors for the first time. Several of these genetic alterations, such as IDH mutation and 1p/19q codeletion, can be assessed at imaging, with approaches including visual inspection, advanced MR and PET techniques, and machine learning reported in the literature. Reliable noninvasive assessment of these genetic features by imaging may allow for improved treatment planning and patient counseling, and an understanding of how the various genetically defined tumor types respond to therapy is useful in interpretation of post-treatment imaging. In the future, the importance of genetic features in glioma diagnosis and treatment will only increase, and it is incumbent upon neuroradiologists to stay abreast of these developments in order to provide optimal patient care.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. World Health Organization histological classification of tumours of the central nervous system. Lyon: International Agency for Research on Cancer; 2007.

    Google Scholar 

  2. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, et al. International Society of Neuropathology–Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014;24(5):429–35.

    Article  Google Scholar 

  3. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707–18.

    Article  Google Scholar 

  4. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149–53.

    Article  CAS  Google Scholar 

  5. Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncology. 2014;16(1):81–91.

    Article  CAS  Google Scholar 

  6. Vogelbaum MA. Towards a genomic definition of completeness of resection? Neuro-Oncology. 2014;16(1):2–3.

    Article  Google Scholar 

  7. Yamashita K, Hiwatashi A, Togao O, Kikuchi K, Hatae R, Yoshimoto K, et al. MR imaging-based analysis of glioblastoma multiforme: estimation of IDH1 mutation status. AJNR Am J Neuroradiol. 2016;37(1):58–65.

    Article  CAS  Google Scholar 

  8. Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, et al. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol. 2012;33(7):1349–55.

    Article  CAS  Google Scholar 

  9. Lee S, Choi SH, Ryoo I, Yoon TJ, Kim TM, Lee SH, et al. Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. J Neuro-Oncol. 2015;121(1):141–50.

    Article  CAS  Google Scholar 

  10. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neuro-Oncol. 2012;107(1):197–205.

    Article  CAS  Google Scholar 

  11. de la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, et al. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro-Oncology. 2016;18(2):283–90.

    Article  Google Scholar 

  12. Pepin KM, McGee KP, Arani A, Lake DS, Glaser KJ, Manduca A, et al. MR elastography analysis of glioma stiffness and IDH1-mutation status. AJNR Am J Neuroradiol. 2018;39(1):31–6.

    Article  CAS  Google Scholar 

  13. Chitneni SK, Yan H, Zalutsky MR. Synthesis and evaluation of a (18)F-labeled triazinediamine analogue for imaging mutant IDH1 expression in gliomas by PET. ACS Med Chem Lett. 2018;9(7):606–11.

    Article  CAS  Google Scholar 

  14. Aibaidula A, Chan AK, Shi Z, Li Y, Zhang R, Yang R, et al. Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro-Oncology. 2017;19(10):1327–37.

    Article  CAS  Google Scholar 

  15. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337–43.

    Article  CAS  Google Scholar 

  16. Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;374(14):1344–55.

    Article  CAS  Google Scholar 

  17. Villanueva-Meyer JE, Wood MD, Choi BS, Mabray MC, Butowski NA, Tihan T, et al. MRI features and IDH mutational status of grade II diffuse gliomas: impact on diagnosis and prognosis. AJR Am J Roentgenol. 2018;210(3):621–8.

    Article  Google Scholar 

  18. Johnson DR, Diehn FE, Giannini C, Jenkins RB, Jenkins SM, Parney IF, et al. Genetically defined oligodendroglioma is characterized by indistinct tumor borders at MRI. AJNR Am J Neuroradiol. 2017;38:678.

    Article  CAS  Google Scholar 

  19. Patel SH, Poisson LM, Brat DJ, Zhou Y, Cooper L, Snuderl M, et al. T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res. 2017;23(20):6078–85.

    Article  CAS  Google Scholar 

  20. Gajjar A, Pfister SM, Taylor MD, Gilbertson RJ. Molecular insights into pediatric brain tumors have the potential to transform therapy. Clin Cancer Res. 2014;20(22):5630–40.

    Article  CAS  Google Scholar 

  21. Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, et al. Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol. 2016;26(5):569–80.

    Article  CAS  Google Scholar 

  22. Meyronet D, Esteban-Mader M, Bonnet C, Joly MO, Uro-Coste E, Amiel-Benouaich A, et al. Characteristics of H3 K27M-mutant gliomas in adults. Neuro-Oncology. 2017;19(8):1127–34.

    Article  CAS  Google Scholar 

  23. Gardiman MP, Fassan M, Orvieto E, D’Avella D, Denaro L, Calderone M, et al. Diffuse leptomeningeal glioneuronal tumors: a new entity? Brain Pathol. 2010;20(2):361–6.

    Article  Google Scholar 

  24. Cho HJ, Myung JK, Kim H, Park CK, Kim SK, Chung CK, et al. Primary diffuse leptomeningeal glioneuronal tumors. Brain Tumor Pathol. 2015;32(1):49–55.

    Article  Google Scholar 

  25. Deng MY, Sill M, Chiang J, Schittenhelm J, Ebinger M, Schuhmann MU, et al. Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathol. 2018;136(2):239–53.

    Article  CAS  Google Scholar 

  26. Thom M, Liu J, Bongaarts A, Reinten RJ, Paradiso B, Jager HR, et al. Multinodular and vacuolating neuronal tumors in epilepsy: dysplasia or neoplasia? Brain Pathol. 2018;28(2):155–71.

    Article  CAS  Google Scholar 

  27. Nunes RH, Hsu CC, da Rocha AJ, do Amaral LLF, Godoy LFS, Watkins TW, et al. Multinodular and vacuolating neuronal tumor of the cerebrum: a new “leave me alone” lesion with a characteristic imaging pattern. AJNR Am J Neuroradiol. 2017;38(10):1899–904.

    Article  CAS  Google Scholar 

  28. Alsufayan R, Alcaide-Leon P, de Tilly LN, Mandell DM, Krings T. Natural history of lesions with the MR imaging appearance of multinodular and vacuolating neuronal tumor. Neuroradiology. 2017;59(9):873–83.

    Article  Google Scholar 

  29. Huse JT, Snuderl M, Jones DT, Brathwaite CD, Altman N, Lavi E, et al. Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathol. 2017;133(3):417–29.

    Article  CAS  Google Scholar 

  30. Johnson DR, Giannini C, Jenkins RB, Kim DK, Kaufmann TJ. Plenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the young. Neuroradiology. 2019. https://doi.org/10.1007/s00234-019-02269-y. [Epub ahead of print].

    Article  Google Scholar 

  31. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, et al. Announcing cIMPACT-NOW: the consortium to inform molecular and practical approaches to CNS tumor taxonomy. Acta Neuropathol. 2017;133(1):1–3.

    Article  Google Scholar 

  32. Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol. 2018;136:805.

    Article  CAS  Google Scholar 

  33. Akkus Z, Ali I, Sedlar J, Agrawal JP, Parney IF, Giannini C, et al. Predicting deletion of chromosomal arms 1p/19q in low-grade gliomas from MR images using machine intelligence. J Digit Imaging. 2017;30(4):469–76.

    Article  Google Scholar 

  34. Chang P, Grinband J, Weinberg BD, Bardis M, Khy M, Cadena G, et al. Deep-learning convolutional neural networks accurately classify genetic mutations in gliomas. AJNR Am J Neuroradiol. 2018;39(7):1201–7.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Mayo Clinic, Rochester, MN, USA

    Derek R. Johnson & Timothy J. Kaufmann

  2. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

    Caterina Giannini

Authors
  1. Derek R. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caterina Giannini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timothy J. Kaufmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy J. Kaufmann .

Editor information

Editors and Affiliations

  1. David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Whitney B. Pope

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Johnson, D.R., Giannini, C., Kaufmann, T.J. (2020). Review of WHO 2016 Changes to Classification of Gliomas; Incorporation of Molecular Markers. In: Pope, W. (eds) Glioma Imaging. Springer, Cham. https://doi.org/10.1007/978-3-030-27359-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-27359-0_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-27358-3

  • Online ISBN: 978-3-030-27359-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation